BSTC:NSD-BioSpecifics Technologies Corp (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 88.53

Change

+0.13 (+0.15)%

Market Cap

USD 0.65B

Volume

0.09M

Average Target Price

USD 94.25 (+6.46%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-12-01 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-11.73 (-7.68%)

USD60.44B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

+2.55 (+1.12%)

USD59.22B 22.32 17.39
REGN Regeneron Pharmaceuticals, Inc

-1.96 (-0.38%)

USD55.06B 18.91 14.53
SGEN Seagen Inc

+7.10 (+4.17%)

USD30.48B 64.32 62.62
BNTX BioNTech SE

-10.23 (-8.23%)

USD29.92B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

+0.04 (+0.03%)

USD26.72B 28.34 26.92
RPRX Royalty Pharma plc

+0.18 (+0.42%)

USD26.64B 22.60 9.74
GMAB Genmab A/S

-0.37 (-0.96%)

USD25.29B 26.59 2.61
BGNE BeiGene, Ltd

-9.20 (-3.60%)

USD21.65B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing BSTC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 55.48% 73% C 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 55.48% 73% C 82% B-
Trailing 12 Months  
Capital Gain 60.55% 68% D+ 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 60.55% 68% D+ 81% B-
Trailing 5 Years  
Capital Gain 95.78% 80% B- 76% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 95.78% 80% B- 74% C
Average Annual (5 Year Horizon)  
Capital Gain 12.18% N/A N/A 69% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.18% N/A N/A 66% D
Risk Return Profile  
Volatility (Standard Deviation) 26.93% N/A N/A 55% F
Risk Adjusted Return 45.22% N/A N/A 67% D+
Market Capitalization 0.65B 67% D+ 61% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 37.46 26% F 28% F
Price/Book Ratio 4.80 44% F 29% F
Price / Cash Flow Ratio 29.14 4% F 12% F
EV/EBITDA 25.94 17% F 30% F
Management Effectiveness  
Return on Equity 13.76% 96% A 85% B
Return on Invested Capital 20.25% 94% A 92% A-
Return on Assets 11.58% 98% A+ 97% A+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.34 89% B+ 88% B+
Short Percent 1.19% 87% B+ 74% C
Beta 0.27 92% A- 89% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.